Colorectal Adenocarcinoma

P2, N=83, Active, not recruiting, Vejle Hospital | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025

Because no significant bias was identified in this limited cohort, an ancestry-based calibration constant or normalization procedure cannot be systematically applied. However, the TMB calling algorithm used by TSO500 relies upon population databases. Therefore, the underlying variants and calculations used to determine TMB should be manually evaluated on a case-by-case basis, particularly for tumors with TMBs close to treatment thresholds in patients of ancestries underrepresented in population databases.

Both assays showed comparable sensitivity in establishing MSI status for CRC and the expanded spectrum of non-CRC tumors. Advantages such as increased number of LMR loci in the Promega assay and the need for only tumor specimen in the Idylla assay increase the utility of these assays in determination of MSI status in a variety of cancers.

P1/2, N=240, Not yet recruiting, A2 Biotherapeutics Inc.

P=N/A, N=291, Not yet recruiting, Shaanxi Provincial People's Hospital; Shaanxi Provincial People's Hospital

P=N/A, N=60, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University

P=N/A, N=0, Not yet recruiting, Beijing Cancer Hospital; Beijing Hospitals Authority

P4, N=200, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University

P2, N=33, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P2, N=30, Not yet recruiting, Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital; Fujian Cancer Hospital

P2, N=130, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of

P2, N=58, Not yet recruiting, Xuancheng People's Hospital; Xuancheng People's Hospital of Anhui Province

P2, N=37, Not yet recruiting, Shanghai East Hospital; Shanghai East Hospital

P1, N=30, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P1/2, N=62, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

INPP4B is highly expressed in CRC tissues and significantly correlated with lymph node metastasis, neural invasion, and patient prognosis. MMP7 may mediate the role of INPP4B in promoting CRC cell migration and invasion.

P3, N=520, Completed, Taizhou Mabtech Pharmaceutical Co.,Ltd | Active, not recruiting --> Completed

P=N/A, N=63, Completed, Institut Cancerologie de l'Ouest | Recruiting --> Completed

P2, N=34, Recruiting, National Cancer Institute, Naples | Trial completion date: Sep 2024 --> Sep 2025

P1, N=272, Active, not recruiting, Genentech, Inc. | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Mar 2025

Next-generation selected cases detected the commonly identified oncogenic variants including those in BRAF, RAS, TP53, and TERT promoter. Overall, we hereby demonstrate that SATB2 IHC may be used to support the diagnosis of ATC.

P1, N=830, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

Additionally, pathway enrichment suggested that NUMB is involved in the Wnt pathway. This study highlights the predictive role of CTNNB1 across cancers, suggesting that CTNNB1 might serve as a potential biomarker for the diagnosis and prognosis evaluation of various malignant tumors.

Key genes in our model, including C5AR1, APOE, CYR1P1, and SPP1, were implicated in COADREAD cell proliferation, invasion, and PD-L1 expression. These insights offer a novel approach to colorectal carcinoma treatment, emphasizing TLS targeting as a potential anti-tumor strategy.

Notably, TNNC1 expression levels were high in all the colon cancer cell lines, particularly in SW480 cells. In this study, we explored the characteristics of PRGs in colon cancer and identified novel biological targets for early individualised treatment and accurate diagnosis of colon cancer, thus contributing to the advancement of clinical oncology.

P2, N=122, Completed, Daiichi Sankyo | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2024

P=N/A, N=60, Recruiting, University of North Carolina, Chapel Hill | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2024 --> Mar 2025

In colon adenocarcinoma, we observe a significantly higher rate of clinical detection for TP53-positive tumors, while in lung adenocarcinoma, the same is true for EGFR-positive tumors. Compared to classical MHNs, this approach eliminates several spurious suppressive interactions and uncovers multiple promoting effects.

P=N/A, N=120, Active, not recruiting, Grupo Espanol Multidisciplinario del Cancer Digestivo | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Apr 2025

P3, N=94, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2025 --> Feb 2025

P3, N=505, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2025 --> Feb 2025

MKMB01 and MKMB02 can reduce pathogen-induced gut-associated disorders and therefore should be further explored for their probiotic potential.

P3, N=480, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P1, N=100, Recruiting, Accent Therapeutics | Not yet recruiting --> Recruiting

P=N/A, N=45, Active, not recruiting, Vastra Gotaland Region | Recruiting --> Active, not recruiting

P2, N=312, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Sep 2024 --> Sep 2025

P2/3, N=104, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Suspended --> Completed | Trial completion date: May 2028 --> Mar 2024 | Trial primary completion date: May 2028 --> Mar 2024

Consistent with existing literature, our findings showed no survival benefit from locoregional treatments such as surgery of the primary tumor or curative radiotherapy at diagnosis. In contrast, resection of hepatic metastases was associated with improved survival outcomes.

Mutant KRAS therapeutics are limited, while Sotorasib and Adagrasib were the only FDA-approved drugs for the treatment of KRASG12C mutated NSCLC. Conclusively, we have designed and developed a dual targeting (MSLN & CEA) CAR protein towards KRAS-mutated PDAC using computational approaches. Alongside, we further recommend to engineer this designed CAR in T-cells and evaluating their therapeutic efficiency in in vitro and in vivo studies in the near future.

This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.

Importantly, we developed a novel AI model that aligns tumors with representative cell lines using RNAseq and methylation data. This model enables us to identify cell lines closely resembling patient tumors, facilitating accurate selection of models needed for in vitro validation.